Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Laboratory and Clinical Evaluation of Screening Agar Plates for Detection of Carbapenem-Resistant Enterobacteriaceae from Surveillance Rectal Swabs
Amos Adler,Shiri Navon-Venezia,Jacob Moran-Gilad,Evgeniya Marcos,David A. Schwartz,Yehuda Carmeli +5 more
TL;DR: MacI appears to be most appropriate medium for the detection of CRE in settings in which multiclonal CRE strains with various MICs to carbapenems are circulating.
Journal ArticleDOI
Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012.
TL;DR: In the United States, E. coli has become increasingly resistant to ciprofloxacin and trimethoprim-sulfamethoxazole (TMP-SMX) in adult female outpatients.
Journal ArticleDOI
Activities of a Nitrofurazone-Containing Urinary Catheter and a Silver Hydrogel Catheter against Multidrug-Resistant Bacteria Characteristic of Catheter-Associated Urinary Tract Infection
TL;DR: In vitro inhibitory activity of a nitrofurazone-coated urinary catheter against 86 recently obtained susceptible and multidrug-resistant clinical isolates of Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Staphylococcus aureus, coagulase-negativestaphylitis, and Enterococcus faecium shows promise for clinical use in the current era of MDR bacteria.
Journal ArticleDOI
High Prevalence of Clarithromycin-Resistant Helicobacter pylori Strains and Risk Factors Associated with Resistance in Madrid, Spain
TL;DR: H. pylori clarithromycin-resistant strains are more frequently found in children, in patients mostly born in Spain, and in individuals who were previously treated for H. plyori infection and that these individuals are more likely colonized with a less virulent H.pylori strain.
Journal ArticleDOI
Dermaseptins from Phyllomedusa oreades and Phyllomedusa distincta. Anti-Trypanosoma cruzi activity without cytotoxicity to mammalian cells.
Guilherme D. Brand,Guilherme D. Brand,José Roberto S. A. Leite,José Roberto S. A. Leite,Luciano P. Silva,Luciano P. Silva,Sérgio de Albuquerque,Maura V. Prates,Maura V. Prates,Ricardo Bentes Azevedo,Vanessa Carregaro,João Santana da Silva,Vanuza C.L. Sá,Reuber Albuquerque Brandão,Carlos Bloch +14 more
TL;DR: DS 01 is a 29-residue-long peptide with a molecular mass of 2793 Da showing antibacterial properties against Gram-positive and Gram-negative bacteria in the range of 3-25 microm, suggesting its therapeutic value especially as an anti-T.